AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.42-0.27 (-0.25%) ▼|ACN225.86+0.94 (+0.42%) ▲|ADBE244.87-6.80 (-2.70%) ▼|AMAT416.92-13.10 (-3.05%) ▼|AMD534.70-27.53 (-4.90%) ▼|AMGN433.20-0.84 (-0.19%) ▼|AMT185.01+3.65 (+2.01%) ▲|AMZN249.28-5.48 (-2.15%) ▼|AVGO330.80-13.53 (-3.93%) ▼|AXP313.09-0.79 (-0.25%) ▼|BA188.42-0.31 (-0.17%) ▼|BAC51.50-0.21 (-0.40%) ▼|BKNG162.76-3.04 (-1.83%) ▼|BLK1,126.59+5.81 (+0.52%) ▲|BMY60.55-0.02 (-0.03%) ▼|BNY142.52+0.43 (+0.30%) ▲|BRK-B529.35+3.67 (+0.70%) ▲|C124.00+0.79 (+0.64%) ▲|CAT736.42+0.78 (+0.11%) ▲|CL93.16+0.49 (+0.53%) ▲|CMCSA21.96+0.19 (+0.85%) ▲|COF200.92+2.06 (+1.04%) ▲|COP146.19+4.46 (+3.15%) ▲|COST991.40+13.39 (+1.37%) ▲|CRM240.54-6.20 (-2.51%) ▼|CSCO107.59-2.26 (-2.06%) ▼|CVS92.09-0.49 (-0.53%) ▼|CVX224.33+5.01 (+2.28%) ▲|DE640.03-10.64 (-1.64%) ▼|DHR229.45-2.05 (-0.89%) ▼|DIS110.26-0.43 (-0.38%) ▼|DUK121.17+2.29 (+1.93%) ▲|EMR160.12-2.04 (-1.26%) ▼|FDX292.83-2.71 (-0.92%) ▼|GD342.83+5.80 (+1.72%) ▲|GE315.38+3.38 (+1.08%) ▲|GEV927.49+1.05 (+0.11%) ▲|GILD156.01-1.36 (-0.86%) ▼|GM83.83+0.17 (+0.20%) ▲|GOOG337.34-7.58 (-2.20%) ▼|GOOGL341.03-8.20 (-2.35%) ▼|GS880.60-10.68 (-1.20%) ▼|HD310.27+2.03 (+0.66%) ▲|HON211.75+1.25 (+0.59%) ▲|IBM231.78-2.34 (-1.00%) ▼|INTC90.65-4.73 (-4.95%) ▼|INTU322.89-7.29 (-2.21%) ▼|ISRG428.39+0.53 (+0.12%) ▲|JNJ255.38+2.10 (+0.83%) ▲|JPM338.55+3.02 (+0.90%) ▲|KO93.02+1.02 (+1.10%) ▲|LIN497.38+4.16 (+0.84%) ▲|LLY1,257.14+5.53 (+0.44%) ▲|LMT548.13+15.49 (+2.91%) ▲|LOW196.90+1.18 (+0.60%) ▲|LRCX266.89-10.57 (-3.81%) ▼|MA614.59-1.74 (-0.28%) ▼|MCD243.11+0.61 (+0.25%) ▲|MDLZ63.87+0.84 (+1.33%) ▲|MDT94.45-1.00 (-1.05%) ▼|META707.26-29.47 (-4.00%) ▼|MMM164.09-1.24 (-0.75%) ▼|MO74.94+1.10 (+1.48%) ▲|MRK146.53+1.34 (+0.92%) ▲|MS180.67-1.43 (-0.79%) ▼|MSFT527.30-12.14 (-2.25%) ▼|MU892.14-39.10 (-4.20%) ▼|NEE79.81+0.85 (+1.08%) ▲|NFLX70.24-2.38 (-3.27%) ▼|NKE36.97-0.17 (-0.46%) ▼|NOW140.95-7.63 (-5.13%) ▼|NVDA214.95-2.29 (-1.05%) ▼|ORCL128.50-5.97 (-4.44%) ▼|PEP130.83+2.45 (+1.91%) ▲|PFE29.52+0.08 (+0.26%) ▲|PG158.47+1.39 (+0.88%) ▲|PLTR186.45-14.06 (-7.01%) ▼|PM204.54+4.64 (+2.32%) ▲|QCOM172.89-5.52 (-3.09%) ▼|RTX192.69+5.74 (+3.07%) ▲|SBUX96.92+0.04 (+0.04%) ▲|SCHW91.81-2.35 (-2.50%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.68+1.29 (+0.63%) ▲|T23.57+0.07 (+0.28%) ▲|TMO687.51-8.98 (-1.29%) ▼|TMUS158.81+1.78 (+1.13%) ▲|TSLA352.27-10.17 (-2.81%) ▼|TXN278.65-0.47 (-0.17%) ▼|UBER70.00-1.28 (-1.79%) ▼|UNH402.21-4.46 (-1.10%) ▼|UNP287.50-1.21 (-0.42%) ▼|UPS96.89-0.95 (-0.97%) ▼|USB58.43+1.04 (+1.80%) ▲|V401.07+1.32 (+0.33%) ▲|VZ44.84+0.44 (+0.99%) ▲|WFC83.59+0.84 (+1.02%) ▲|WMT118.73+0.86 (+0.73%) ▲|XOM178.13+3.45 (+1.98%) ▲|AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.42-0.27 (-0.25%) ▼|ACN225.86+0.94 (+0.42%) ▲|ADBE244.87-6.80 (-2.70%) ▼|AMAT416.92-13.10 (-3.05%) ▼|AMD534.70-27.53 (-4.90%) ▼|AMGN433.20-0.84 (-0.19%) ▼|AMT185.01+3.65 (+2.01%) ▲|AMZN249.28-5.48 (-2.15%) ▼|AVGO330.80-13.53 (-3.93%) ▼|AXP313.09-0.79 (-0.25%) ▼|BA188.42-0.31 (-0.17%) ▼|BAC51.50-0.21 (-0.40%) ▼|BKNG162.76-3.04 (-1.83%) ▼|BLK1,126.59+5.81 (+0.52%) ▲|BMY60.55-0.02 (-0.03%) ▼|BNY142.52+0.43 (+0.30%) ▲|BRK-B529.35+3.67 (+0.70%) ▲|C124.00+0.79 (+0.64%) ▲|CAT736.42+0.78 (+0.11%) ▲|CL93.16+0.49 (+0.53%) ▲|CMCSA21.96+0.19 (+0.85%) ▲|COF200.92+2.06 (+1.04%) ▲|COP146.19+4.46 (+3.15%) ▲|COST991.40+13.39 (+1.37%) ▲|CRM240.54-6.20 (-2.51%) ▼|CSCO107.59-2.26 (-2.06%) ▼|CVS92.09-0.49 (-0.53%) ▼|CVX224.33+5.01 (+2.28%) ▲|DE640.03-10.64 (-1.64%) ▼|DHR229.45-2.05 (-0.89%) ▼|DIS110.26-0.43 (-0.38%) ▼|DUK121.17+2.29 (+1.93%) ▲|EMR160.12-2.04 (-1.26%) ▼|FDX292.83-2.71 (-0.92%) ▼|GD342.83+5.80 (+1.72%) ▲|GE315.38+3.38 (+1.08%) ▲|GEV927.49+1.05 (+0.11%) ▲|GILD156.01-1.36 (-0.86%) ▼|GM83.83+0.17 (+0.20%) ▲|GOOG337.34-7.58 (-2.20%) ▼|GOOGL341.03-8.20 (-2.35%) ▼|GS880.60-10.68 (-1.20%) ▼|HD310.27+2.03 (+0.66%) ▲|HON211.75+1.25 (+0.59%) ▲|IBM231.78-2.34 (-1.00%) ▼|INTC90.65-4.73 (-4.95%) ▼|INTU322.89-7.29 (-2.21%) ▼|ISRG428.39+0.53 (+0.12%) ▲|JNJ255.38+2.10 (+0.83%) ▲|JPM338.55+3.02 (+0.90%) ▲|KO93.02+1.02 (+1.10%) ▲|LIN497.38+4.16 (+0.84%) ▲|LLY1,257.14+5.53 (+0.44%) ▲|LMT548.13+15.49 (+2.91%) ▲|LOW196.90+1.18 (+0.60%) ▲|LRCX266.89-10.57 (-3.81%) ▼|MA614.59-1.74 (-0.28%) ▼|MCD243.11+0.61 (+0.25%) ▲|MDLZ63.87+0.84 (+1.33%) ▲|MDT94.45-1.00 (-1.05%) ▼|META707.26-29.47 (-4.00%) ▼|MMM164.09-1.24 (-0.75%) ▼|MO74.94+1.10 (+1.48%) ▲|MRK146.53+1.34 (+0.92%) ▲|MS180.67-1.43 (-0.79%) ▼|MSFT527.30-12.14 (-2.25%) ▼|MU892.14-39.10 (-4.20%) ▼|NEE79.81+0.85 (+1.08%) ▲|NFLX70.24-2.38 (-3.27%) ▼|NKE36.97-0.17 (-0.46%) ▼|NOW140.95-7.63 (-5.13%) ▼|NVDA214.95-2.29 (-1.05%) ▼|ORCL128.50-5.97 (-4.44%) ▼|PEP130.83+2.45 (+1.91%) ▲|PFE29.52+0.08 (+0.26%) ▲|PG158.47+1.39 (+0.88%) ▲|PLTR186.45-14.06 (-7.01%) ▼|PM204.54+4.64 (+2.32%) ▲|QCOM172.89-5.52 (-3.09%) ▼|RTX192.69+5.74 (+3.07%) ▲|SBUX96.92+0.04 (+0.04%) ▲|SCHW91.81-2.35 (-2.50%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.68+1.29 (+0.63%) ▲|T23.57+0.07 (+0.28%) ▲|TMO687.51-8.98 (-1.29%) ▼|TMUS158.81+1.78 (+1.13%) ▲|TSLA352.27-10.17 (-2.81%) ▼|TXN278.65-0.47 (-0.17%) ▼|UBER70.00-1.28 (-1.79%) ▼|UNH402.21-4.46 (-1.10%) ▼|UNP287.50-1.21 (-0.42%) ▼|UPS96.89-0.95 (-0.97%) ▼|USB58.43+1.04 (+1.80%) ▲|V401.07+1.32 (+0.33%) ▲|VZ44.84+0.44 (+0.99%) ▲|WFC83.59+0.84 (+1.02%) ▲|WMT118.73+0.86 (+0.73%) ▲|XOM178.13+3.45 (+1.98%) ▲|
21.2 C
New York
Friday, October 16, 2026

Tag: prescription

newssourceFORcompanycontentinformation1releasesmarket

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

JellyFil Discloses 2026 Botanical Ingredient Sourcing, cGMP Manufacturing Standards, Caffeine Content, and Consumer Safety Considerations for Its Premium Gummy Dietary Supplement

JellyFil discloses 2026 gummy supplement ingredient origins, cGMP manufacturing standards, caffeine content, and drug interaction guidance.

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —

Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients

SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful...

TWL Announces Expanded Online Access to GLP-1 Weight-Loss Care With Insurance and Self-Pay Options

Telehealth program combines licensed medical care, insurance coordination, coaching and multiple prescription pathways for eligible patients 
Telehealth program combines licensed medical care, insurance coordination, coaching and multiple prescription pathways for eligible patients

Zealthy Expands Insurance Coordination for GLP-1 Weight-Loss Medications

This program broadens prior-authorization and coverage-support services for eligible patients seeking prescription weight-management treatment 
This program broadens prior-authorization and coverage-support services for eligible patients seeking prescription weight-management treatment

AM Rx Announces Expanded Online Access and Insurance Support for Zepbound

Telehealth company introduces an insurance-first weight-management pathway designed to help eligible patients navigate Zepbound coverage, prior authorization and ongoing virtual care 
Telehealth company introduces an insurance-first weight-management pathway designed to help eligible patients navigate Zepbound coverage, prior authorization and ongoing virtual care

RoenRx Releases 2026 Weight-Loss Program Pricing and Treatment Cost Overview

New York, NY, June 23, 2026 (GLOBE NEWSWIRE) -- RoenRx, a telehealth platform providing medically supervised weight-loss care, today released updated 2026 pricing information for its weight-loss program, detailing membership costs, insurance-supported GLP-1 treatment options, compounded medication pricing, bundled care plans, and subscription terms. The pricing overview is intended to provide prospective patients with greater transparency regarding the potential costs associated with RoenRx's weight-management services and available treatment pathways.

Curaleaf International Launches CPD-Accredited Medical Cannabis Education Platform for UK Healthcare Professionals

LONDON, June 23, 2026 /PRNewswire/ -- Curaleaf International, one of the global leaders in medical cannabis, today announces the launch of the Curaleaf Education...

New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway

Drugmakers run the largest direct-to-consumer advertising category in the United States. New 5W research finds AI citation share does not follow the ad budget...

FDA Approves Labeled Strength Update of TWIRLA® (levonorgestrel/ethinyl estradiol) Birth Control Patch

FLORHAM PARK, N.J., June 19, 2026 (GLOBE NEWSWIRE) -- Exeltis USA, Inc. (Exeltis), a global pharmaceutical company specializing in women’s health, announced that the U.S. Food and Drug Administration (FDA) has approved an update to the labeled strength of TWIRLA® (levonorgestrel and ethinyl estradiol) transdermal system. The new labeled strength will begin to appear on the market in September or October of 2026.

Quay Prescription Glasses Review (2026): How Quay Balances Style, Affordability, and Daily Comfort According to Consumer365

NEW YORK, June 19, 2026 /PRNewswire/ -- Prescription eyewear is no longer only seen as a practical purchase. Many consumers now want products that...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPrescription

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers